Repression of autophagy in diabetic cardiomyopathy via  RhoA/ROCK2 signaling pathways by Fu, Cheng Yu & Fen, Guo Xiao
  
Indian Journal of Experimental Biology 






Repression of autophagy in diabetic cardiomyopathy via  
RhoA/ROCK2 signaling pathways 
Cheng Yu Fu1* & Guo Xiao Fen2 
1The No.1 Clinical Medical College of Shanxi Datong University, Datong No.5 People's Hospital, Shanxi, China 
2Medical College of Shanxi Datong University, Shanxi, China 
Received 02 January 2020; revised 21 April 2020 
Activated RhoA and ROCK is associated with many cardiovascular diseases (CVD) such as congestive heart failure 
(CHF), atherosclerosis and hypertension. However, the role of RhoA/ROCK2 signaling pathway in initiating diabetic 
cardiomyopathy (DCM) has not been fully elucidated. Here, we studied the role of RhoA/ROCK2 signaling pathway in 
induction of DCM through autophagy suppression in diabetic rat animal models. Broadly, we investigated the potential role 
and mechanism of diabetes induced myocardial dysfunction in rats. DCM was induced by injections of streptozocin (STZ) 
in experimental Wistar rats. The experimental rats were randomized to be treated with fasudil and lentivirus carrying the 
RhoA cDNA. Haemodynamic changes, assessment of cardiac weight index, histopathological examinations, cardiomyocyte 
autophagy and expression of RhoA and ROCK2 mRNAs were compared between groups. The expression of RhoA and 
ROCK mRNAs was found significantly increased in cardiac tissues compared with control group. The RhoA overexpression 
significantly decreased the values of left ventricular ejection fraction (LVEF), ±dp/dtmax and repressed autophagy. 
RhoA/ROCK2 signaling pathway repressed autophagy in diabetic cardiomyopathy indicating that it may serve as a potential 
therapeutic target for DCM treatment.  
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Diabetic cardiomyopathy (DCM) has been defined as 
the cardiac dysfunction in diabetic patients in the 
absence of coronary artery disease, hypertension  
or changes in blood pressure1. DCM, as a chronic 
complication of diabetes mellitus, is highly 
characterized by abnormalities in both myocardial 
structure as well as function2. The main clinical 
features of DCM are decreased values of left 
ventricular ejection fraction (LVEF), cardiomyocyte 
hypertrophy and myocardial fibrosis3. Other 
hallmarks of DCM include hyperglycemia, insulin 
resistance, excessive free radical production, 
mitochondrial and endothelial dysfunction and cell 
death, and cell death is considered to be the terminal 
pathway of cardiomyocytes during DCM2,4,5. 
Dysregulation in cardiovascular and reproductive 
systems along with nephropathy, retinopathy, 
neuropathy and diabetic foot ulcer may arise in the 
advanced stages of diabetes. Furthermore, high 
glucose level also encourages proliferation of cancer 
cells, development of osteoarthritis and facilitates 
multiple infections6. Fan et al.7 found that glucagon-
like peptide 1 (GLP-1), a glucagon incretin hormone 
released from the gut endocrine L-cells, might reverse 
myocardial hypertrophy through the PKA/RhoA/ 
ROCK2 signaling pathway.  
While investigating the role of cardiomyocyte 
RhoA and of ROCK2 in DCM development, the 
effects of heterozygous deletion of ROCK2 
(ROCK2+/-) on cardiac function in a CD1 mouse 
model of type 1 diabetes induced by streptozotocin 
(STZ) showed that deletion of ROCK2 and 
cardiomyocyte RhoA protects the diabetic heart8. 
Further, Shimokawa et al.9 suggest that Rho-kinase is 
substantially involved in the pathogenesis of a wide 
range of cardiovascular diseases, and Rho-kinase 
inhibitors may be useful for treating cardiovascular 
diseases (CVD)9.  
Morphologically, cells death may occur due to 
apoptosis, autophagy, necrosis or entosis. However, 
the specific mechanism of DCM has not been fully 
elucidated, and there is no effective treatment 
available for treating DCM in diabetic patients. 
Autophagic cell death is a degradation process to 
remove damaged proteins and dysfunctional 
organelles initiated by the formation of auto-








binding protein Ras homolog gene family member A 
(RhoA) and its effector Rho-associated kinase 
(ROCK) play a significant role in cardiovascular 
systems. RhoA has been reported to regulate cell 
functions such as cell movement, autophagy and 
apoptosis10, while as ROCK is one of the most 
important effectors of RhoA, accumulating evidence 
has demonstrated that RhoA/ROCK2 signaling 
pathway is implicated in hypertension, cerebral 
vasospasm, heart failure, pulmonary hypertension, 
atherosclerosis, hemangioma, ischemia reperfusion 
injury and so on11,12. There is growing evidence that 
the ROCK pathway plays an important role in the 
development of cardiovascular diseases and that 
inhibition of ROCK activity by selective ROCK 
inhibitors would be beneficial in treating cardio-
vascular diseases13. 
ROCK1 is preferentially expressed in the liver, 
lung, kidney, spleen and testes, whereas ROCK2 is 
most highly expressed in the heart and brain, and 
ROCK2 acts as a prominent regulator of autophagic 
flux and caspase-3 activities in neurodegenerative 
diseases14. Moreover, the RhoA/ROCK2 pathway is 
implicated in DCM and acute inhibition of ROCK2 
improves contractile function of hearts in type 1 
diabetic rats both in vitro and in vivo15. Activation of 
RhoA/ROCK2 signaling pathway has been found to 
play a critical role in the development of DCM, and 
the ROCK2 might be a significant therapeutic target 
for treating DCM condition16.  
Lin28, a highly conserved RNA-binding protein, 
protects against DCM through PKA/ROCK2 
dependent pathway. Its overexpression significantly 
improves left ventricular ejection fraction (LVEF), 
and promotes autophagy in diabetic mice, and might 
serve as a potential therapeutic target17. Though the 
RhoA/ROCK2 signaling pathway is known to play an 
important role in DCM, its mechanism still remains 
unelucidated. Hence, in the present study, we tried to 
understand the role of the RhoA/ROCK2 signaling 
pathway in induction of DCM through autophagy 
suppression in diabetic rat animal models. 
 
Materials and Methods 
Animal model preparation for in vivo experiments 
Forty male Wistar rats (200-220 g) were purchased 
from Beijing Vital River Laboratory Animal 
Technology Co. Ltd. (Beijing, China). Diabetes was 
induced by intraperitoneal injection of streptozotocin 
(STZ, Sigma, St. Louis, MO) dissolved in 0.1 mL 
citrate buffer (pH 4.5) at 50 mg/kg for 5 days, while 
the control group was injected with citrate buffer17. 
Blood sample was obtained from all rats through the 
caudal vein after one week of STZ injections and the 
values of blood glucose were measured using a 
reflectance meter (Accu-Chek, Roche Diagnostic, 
Mannheim, Germany)17. The values above 16.6 mmol/L 
were considered as diabetes. After the induction of 
diabetes for 8 weeks, the rats were randomly divided 
into four groups (n=10): (i) Control group; (ii) STZ 
group; (iii) Fasudil group (fasudil is an inhibitor of 
RhoA/ROCK2 signaling pathway); and (iv) Over-
expression of RhoA group. Lentivirus containing 
RhoA cDNA (30 µL, 1×109 TU/mL) was delivered 
via three separate intramyocardial injections 
(designed and purchased from Genechem, Shanghai, 
China). After 4 weeks, the Wistar rats were sacrificed.  
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total-RNA from the left ventricular myocardial 
tissue was extracted using Trizol reagent (1596-026) 
(Invitrogen Life Technologies, Carlsbad, CA, USA), 
and reverse transcription was conducted using 
RevertAidTM Reverse Transcriptase (EP0441) 
(Thermo Fisher Scientific Inc., Rockford, IL, USA). 
Quantitative PCR was conducted using FastStart 
Universal SYBR Green PCR Master mix 
(4913914001) (Rox; 11929100) (Roche, Indianapolis, 
IN, USA), according to manufacturer's procedure. 
Forward (F) and reverse (R) primers were used as 
follows: RhoA, F: 5'-ACCAGTTCCCAGAGGTGTA 
TGT-3' and R: 5'-TTGGGACAGAAGTGCTTGAC 
TTC-3'; ROCK, F: 5'-GAG CAACTATGATGTGCCTG 
AAAAAT-3' and R: 5'-GATGTCGTTTGATTTCTT 
CTAC-3'; GAPDH, F, 5'-ATGGGGAAGGTGAAGG 
TCG-3' and R, 5'-GGGGTCATTGATGGCAACA 
ATA-3' (Invitrogen Life Technologies, Carlsbad, CA, 
USA). All measurements were performed in triplicate, 
and measured by ABI Prism 7300 sequence detection 
system (Applied Biosystems). The fold-change of  
RhoA and ROCK was calculated using the 2-ΔΔCT 
method.  
 
Measurement of cardiac function 
Wistar rats were anesthetized with 25% urethane 
(1.0 g/kg). Cardiac dimensions and function were 
detected by M-mode echocardiography. The values of 
left ventricular ejection fraction (LVEF), maximal 
rate of ventricular pressure rise (+dp/dtmax) and 
decline (-dp/dtmax) were obtained according to the 
manufacturer’s procedure, which represents three 
continuous cardiac cycles17.  




Evaluation of autophagosomes by TEM 
The rats’ hearts were retrograde perfused using 
phosphate buffer saline (PBS; pH 7.4) and 2% 
glutaraldehyde diluted in 0.1 M cacodylate buffer. 
Using 2% osmium tetroxide in 0.1M cacodylate 
buffer and 1% aqueous uranyl acetate was used to fix 
the tissue16. Then, the tissue was prepared for 
transmission electron microscopy (TEM). A JEOL 
1200 EX TEM (operating at 30-120 KV with a digital 
camera) was used to image the sections. 
Ultrastructural studies were adopted to explore the 
double membrane-bound autophagic vacuoles. The 
alternations of myofibril and mitochondrial 
ultrastructure were detected by electron micrographs 
(original magnification X43000). 
 
Western blot analysis 
Whole-tissue protein lysates were prepared and 
subjected to western blotting18. Primary antibody 
LC3, Beclin-1, and RhoA were purchased from Cell 
Signaling Technology, Inc. (Beverly, MA, USA). 
Antibodies GAPDH and β-actin were purchased from 
Bioworld Technology, Inc. (Louis Park, MN, USA). 
 
Lentivirus containing RhoA cDNA 
Lentivirus carrying RhoA cDNA was designed and 
purchased from Genechem Company (Shanghai, China).  
 
Statistical analysis 
The statistical significance of differences between 
different treatments was analyzed with two-sided 
unpaired Student's t tests. Results were considered to 




Effect of RhoA/ROCK2 signaling pathway on blood glucose levels 
After four weeks of intraperitoneal injection of 
STZ, the Wistar rats had high values of blood glucose, 
compared to the control group injected with citrate 
buffer. Student’s t tests showed a statistical 
significance, suggesting successful model of DCM 
rats (Table 1). The STZ also significantly induces the 
decrease of body weight. However, compared with 
the STZ group, fasudil group and overexpression of 
RhoA group could not alter the values of blood 
glucose and the body weight. Results indicated that 
both activated or inactivated RhoA/ROCK2 signaling 
pathway did not affect blood glucose and body weight 
in DCM rats. 
 
RhoA/ROCK2 signaling pathway is activated in DCM 
The expression of RhoA was detected by western 
blot analysis and qRT-PCR analysis (Fig. 1 A and B). 
The RNA and protein levels of RhoA were elevated in 
STZ group, which indicates that RhoA/ROCK2 
signaling pathway was activated in DCM rats. Fasudil 
partly abrogated STZ induced elevated expression of 
RhoA (compare lanes 3 and 2 in Fig. 1A), which 
indicates that although fasudil is a universally 
recognized inhibitor of RhoA/ROCK2 signaling 
pathway, it could not fully inhibit RhoA/ROCK2 
pathways in the current study. Fasudil could not treat 
diabetic patients, and lentivirus carrying the RhoA 
cDNA greatly promoted the expression of RhoA, 
suggesting that the lentivirus worked in the current 
experiment (compare lanes 4 and 2 in Fig. 1A). 
 
A significant effector of RhoA called ROCK2 was 
elevated in three groups (STZ, fasudil, and over-
expression of RhoA group) is represented in Fig. 1C. 





Fig. 1 — RhoA/ROCK signaling pathway is activated in DCM rats. Wistar rat’s left ventricular myocardial tissue was extracted for 
detect of expression of RhoA and ROCK by western blot analysis and qRT-PCR analysis. (A) Expression of RhoA was detected by 
Western blot analysis, and the semi-quantified expression of RhoA is presented on the right; Expression of (B) RhoA; and (C) ROCK 
were detected by qRT-PCR analysis. [Columns, means three independent tests; bars, S.D. *P <0.05 vs. STZ] 
 
 
Table 1—Effects of over expression of RhoA on the body weight 
and blood glucose (X±SD) in all four groups (Control, STZ, 
fasudil and RhoA expression group) 
Group No. Body weight (g) Blood glucose (mmol/L) 
Cont. 10 4w 8w 12w 4w 8w 12w 
STZ 10 239±13 251±18 286±14 5.7±0.7 5.5±0.3 5.6±0.5 
fasudil 10 212±16* 190±14* 182±11* 19.5±0.4* 18.7±0.3* 18.1±0.5* 
RhoA 10 205±10 200±13 191±14 18.0±0.3 18.2±0.5 18.3±0.2 
 




pathway was activated, and fasudil alone could not 
inactive RhoA/ROCK2 pathway. 
 
Effect of RhoA/ROCK2 signaling pathway on DCM rat’s 
cardiac functions 
Hemodynamic measurements were performed in 
DCM rats to measures the blood pressure. Compared 
to the control group, the DCM rats have lower 
percentage of LVEF (Fig. 2A, column 2), which is 
consistent with the clinical features in DCM patients. 
Treatment with fasudil partly improved the 
percentage of LVEF, suggesting that the activity of 
RhoA/ROCK2 signaling pathway is related to the 
cardiac function of DCM rats (compare columns 3 
and 2 in Fig. 2A). On the other hand, overexpression 
of RhoA aggravated the heart failure in DCM rats. 
The percentage of LVEF was lower than the STZ 
group.  
The ±dp/dtmax was decreased in DCM rats 
(compare columns 2 and 1 in Fig. 2 B and C). Fasudil 
significantly enhanced ±dp/dtmax compared with the 
STZ group. The ±dP/dtmax was further decreased in 
the overexpression of RhoA group compared with the 
STZ group (columns 3 and 4 in Fig. 2 B and C). All 
results indicated that RhoA/ROCK2 signaling 
pathway is activated in DCM, and manipulating the 
RhoA/ROCK2 signaling pathway activity can reverse 
cardiac functions in DCM condition.  
 
RhoA/ROCK2 signaling pathway repressed autophagy in DCM 
The RhoA/ROCK2 signaling pathway has been 
reported to regulate cell functions such as cell movement, 
autophagy and apoptosis10. However, in DCM, it is not 
clear whether the RhoA/ROCK2 signaling pathway 
regulates autophagy or not. Therefore, expression of 
LC3 and Beclin 1 was studied. Compared with the 
control group, LC3 II was decreased together with 
Beclin 1, indicating that autophagy was repressed 
(compare lanes 2 and 1 in Fig. 3). Fasudil partly 




Fig. 2 — RhoA/ROCK signaling pathway affects the cardiac functions. (A) Left ventricular ejection fraction (LVEF) of each group;  
(B and C) First derivative of the left ventricular pressure (±dp/dtmax). [Columns and error bars represent means and SD. n = 10 rats per 




Fig. 3 — RhoA/ROCK signaling pathway repressed autophagy in DCM. (A) Wistar rat’s left ventricular myocardial tissue was extracted 
to detect the expression of LC3 and Beclin1 by western blot analysis; Semi-quantified expression of (B) LC3 II; and (C) Beclin1; and (D) 
Effect of RhoA/ROCK signaling pathway on the number of intracellular autophagosomes in the DCM rat. [Activated RhoA/ROCK 
signaling pathway suppressed the formation of intracellular autophagosomes. Representative TEM images from different groups] 
 




expression of LC3 II and Beclin 1 were partly 
reversed (compare lanes 2 and 3 in Fig. 3). Results 
suggested that manipulation of RhoA/ROCK2 
signaling pathway may reverse the autophagy 
suppression. Collectively, results indicated that 
activated RhoA/ROCK2 signaling pathway 
aggravated the heart failure in DCM. 
 
Discussion  
Among the Ras and Ras-like proteins such as ras 
homolog gene family (Rho), Rab, Ran, Arf, ras 
homolog gene family member A (RhoA) and the 
effector Rho-associated kinase (ROCK) have been 
investigated in detail19-22. Accumulating evidence has 
demonstrated that RhoA/ROCK2 signaling pathway 
play vital roles in regulating cells adhesion, migration, 
motility, contraction, apoptosis, and proliferation 
through regulating the organization of actin 
cytoskeleton23. RhoA/ROCK2 signaling pathway also 
regulates autophagy19. On other hand, RhoA/ROCK2 
signaling pathway is responsible for modulating the 
cardiovascular system by control gene and protein 
expression. So far, RhoA/ROCK2 signaling pathway 
has been reported to participate in the development of 
hypertension24, metabolic syndrome25, coronary artery 
spasm26, acute ischemic stroke27, pulmonary 
hypertension28 and congestive heart failure29.  
 
The current study investigated the relation between 
RhoA/ROCK2 signaling pathway and DCM. The 
Framingham Heart study1 showed that the incidence 
of heart failure (HF) is 2-5 times higher in diabetic 
men and women. The DCM mainly impaired left 
ventricular and passive relaxion, cardiomyocyte 
hypertrophy and myocardial fibrosis30. The DCM has 
been reported to be associated with inflammation, 
oxidative stress, myocardial fibrosis, mitochondrial 
damage, myocardial apoptosis and autophagy. The 
present study found that RhoA/ROCK2 signaling 
pathway plays a role in regulating autophagy in DCM.  
 
Body weight (g) and blood glucose level (mmol/L) 
of DCM Wistar rats were measured on a daily basis. 
Both body weight and blood glucose level recorded 
for 4, 8 and 12 weeks are given in Table 1. Results 
indicated that STZ group rats have lower body weight 
and higher blood glucose (above 16.6 mmol/L). The 
DCM rats were used as successful animal models. 
 
The study investigated role of RhoA/ROCK2 
signaling pathway and overexpression of RhoA on the 
body weight and the blood glucose levels in DCM rats 
as compared to the STZ group. The results indicated 
that the RhoA/ROCK2 signaling pathway did not 
regulate the glycometabolism. Furthermore, 
hemodynamic measurements were performed in DCM 
rats. It was found that when compared to the STZ 
group, fasudil could partly increase the percentage of 
LVEF and maximum rate of ventricular pressure 
(±dp/dtmax) (Fig. 2). However, fasudil could not 
completely improve the cardiac functions, whereas 
overexpression of RhoA aggravated the heat failure in 
DCM rats.  
 
The left ventricular myocardial tissue specimen 
was collected after sacrifice of rats and the western 
blotting and qRT-PCR analysis was carried out  
(Fig. 1). It was found that the RhoA expression was 
elevated in STZ group. Fasudil partly abrogated the 
high expression of RhoA in DCM, and the ROCK2 
was regulated by RhoA.  
 
Role of the RhoA/ROCK2 signaling pathway in 
autophagy was studied using expression of LC3 and 
Beclin 1 and the results are presented in Fig. 3. 
Results showed that the autophagy was suppressed in 
DCM, and the overexpression aggravated the 
autophagy repression (compare lanes 4 and 2 in  
Fig 3A, the expression of LC3 II and Beclin 1 was 
decreased) as reported earlier by Sun et al.17, and 
inhibition of the RhoA/ROCK2 signaling pathway 
could partly reverse the autophagy repression 
(compare lanes 3 and 2 in Fig. 3A, the expression of 
LC3 II and Beclin 1 were increased). The TEM 
results showed that activated RhoA/ROCK2 signaling 
pathway suppressed the formation of intracellular 
autophagosomes (Fig. 3D). Gao et al.31 also found 
that fasudil suppressed ROCK levels, promoted 
autophagy via increasing the LC3-II/LC3-I ratio, 
Beclin-1 expression, and the number of 
autophagosomes in H9c2 cells treated with high 
glucose, and such effects could be abrogated by 
inhibitors of autophagy. 
 
Conclusion 
In this study, results indicated that both activated 
or inactivated RhoA/ROCK2 signaling pathway did 
not affect blood glucose and body weight in DCM 
rats. Significant effector of RhoA called ROCK2 was 
elevated in three experimental groups STZ, fasudil, 
and RhoA overexpression group. Additionally, 
RhoA/ROCK2 pathway was activated in diabetic rats, 




and fasudil alone could not inactive RhoA/ROCK2 
pathway. Levels of microtubule-associated protein 
light chain 3 II (LC3 II) and Beclin 1 were decreased, 
indicating repression of autophagy. Manipulating the 
activity of RhoA/ROCK2 signaling pathway may 
release the autophagy suppression. Conclusively, 
when RhoA/ROCK2 signaling pathway was activated 
in DCM, it aggravated the heart failure through 
repression of autophagy, which provided a new target 
for clinical treatment in DCM patients.  
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